NCT02204163已完成3 期
A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome
LG Life Sciences3 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2014年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 34
- 试验地点
- 3
- 主要终点
- Change from baseline in height SDS (Standard Deviation Score)
研究概览
简要总结
Evaluate the efficacy and safety after treatment of Eutropin® inj. compared to Genotropin® in infants/toddlers with Prader-Willi syndrome
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pediatric patients with PWS confirmed by methylation PCR genetic testing
- •Prepubertal pediatric patients (Tanner's Pubertal stage I) at screening
- •Pediatric patients who have never been treated with hGH prior to screening, or who had been treated with hGH for less than 6 months if they had a treatment history, and whose last administration was made 6 months prior to screening
- •Pediatric patients with normal thyroid function at screening (Those with normal function through a hormonal therapy were allowable.)
- •Pediatric patients whose parents or LARs signed the informed consent form in writing after receiving the explanation about the purpose, method, effects, etc. of the clinical study, and who also signed the informed consent form in writing if they are capable of reading and understanding writing.
排除标准
- •Pediatric patients who are accompanied by other causes for growth retardation as follows except for PWS at screening
- •: Chronic renal failure (including the case in which renal transplantation has been undergone), Silver-Russell syndrome, Turner's syndrome, Seckel syndrome, Down's syndrome, Noonan syndrome, Cushing's syndrome, congenital infections, psychiatric disorders, chronic debilitating diseases, etc.
- •Pediatric patients with malignancy or a history of malignancy at screening
- •Pediatric patients with severe respiratory disturbance, or sleep apnoea or a history of respiratory infections with an unknown cause at screening. However, those whose condition had been confirmed to be eligible to participate in the clinical study on investigator's judgment were allowed to participae in the study.
- •Pediatric patients with impaired fasting glucose, diabetes, and diabetic retinopathy at screening
- •Pediatric patients whose epiphyses are closed with a growth rate of ≤1 cm/year at screening
- •Pediatric patients who are being administered any drug that may have an effect on the secretion and actions of hGH (estrogen, androgen, anabolic steroids, corticosteroids, GnRH analogs, thyroxine, aromatase inhibitors, etc.) or anticonvulsants and cyclosporin at screening, and have been administered any of them for a long period of time within 6 months prior to screening (However, those who have been administered a thyroxine preparation for ≥4 weeks on a stable dose [allowable in case the investigator determines the dose is stable even though it is changeable based upon the weight of the pediatric patient] were allowed to participate in the clinical study.)
- •Pediatric patients who are being administered any drug (e.g. methylphenidate) for treatment of hyperactivity disorders including attention deficit hyperactivity disorder (ADHD) at screening
- •Pediatric patients who are hypersensitive to somatropin or any excipient of the investigational product (cresol or glycerol) or who have a relevant history of hypersensitivity
- •Pediatric patients who have participated in any other clinical studies after enrolled in this study or who had participated in any other clinical studies within 3 months prior to enrollment in this clinical study
- •Pediatric patients in whom this clinical study is considered to be difficult to be conducted for any other reasons on investigator's judgment
研究组 & 干预措施
Eutropin
Experimental
Eutropin 0.24mg/kg/week
干预措施: Eutropin (Drug)
Genotropin
Active Comparator
Genotropin 0.24mg/kg/week
干预措施: Genotropin (Drug)
结局指标
主要结局
Change from baseline in height SDS (Standard Deviation Score)
时间窗: baseline and 52 weeks
Change from baseline in Percent body fat (%)
时间窗: baseline and 52 weeks
Change from baseline in Lean body mass (g)
时间窗: baseline and 52 weeks
次要结局
- Change from baseline in height SDS(baseline, 16 and 28 weeks)
- Change from baseline in IGF-1 (ng/mL) and IGF-1 SDS(baseline, 28, and 52 weeks)
- Change from baseline in head circumference (cm)(baseline, 16, 28 and 52 weeks)
- Change from baseline in Bone mineral density (g/cm)(baseline and 52 weeks)
- Change from baseline in height (cm)(baseline, 16, 28 and 52 weeks)
- Change from baseline in IGFBP-3 (ng/mL) and IGFBP-3 SDS(baseline, 28, and 52 weeks)
- Change from baseline in Bone age (month)(baseline and 52 weeks)
- Change from baseline in height velocity (cm/year)(baseline, 16, 28 and 52 weeks)
- Change from baseline in motor development (score) by Bayley Scale(baseline, 28 and 52 weeks)
- Change from baseline in cognitive development (score) by Bayley Scale(baseline, 28 and 52 weeks)
- Change from baseline in weight SDS(baseline 16, 28 and 52 weeks)
- Change from baseline in BMI (kg/m2) (Body Mass Index)(baseline, 16, 28 and 52 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
不适用
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast CancerNeoplasm, BreastBreast DiseasesBreast CancerNCT03756064Zhejiang Cancer Hospital100
已完成
3 期
Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL OvuleTrichomonal VaginitisCandidal VulvovaginitisMixed Vaginal InfectionsBacterial VaginosisNCT06056947Ege University577
进行中（未招募）
3 期
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific AntibodyMalignant AscitesNCT06432296Wuhan YZY Biopharma Co., Ltd.312
已完成
3 期
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 MutationsThoracic NeoplasmsNCT01024413Chinese Society of Lung Cancer256
已完成
3 期
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast CancerBreast CancerNCT03433313EirGenix, Inc.807